) will license  TransTech Pharma’s (High Point, NC, 

)  portfolio of large- and small-molecule compounds that target the receptor for  advanced glycation end products (RAGE), which have potential use in treating  Alzheimer’s disease. The most advanced molecules include TTP4000, a large-molecule  compound expected to enter Phase 1 trials this year, and TTP488, a  small-molecule compound that has completed a Phase 2a study.

News

Pfizer (New York, NY, www.pharmtech.com) will license TransTech Pharma's (High Point, NC, www.ttpharma.com) portfolio of large- and small-molecule compounds that target the receptor for advanced glycation end products (RAGE), which have potential use in treating Alzheimer's disease.